Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Thursday's Small-Cap Winners & Losers

Continental Materials (CUO) fell 2.4% to $28.20 after its second-quarter earnings declined from a year ago.

The company earned $1.19 million, or 74 cents a share, down from $1.43 million and 89 cents a share last year. Sales rose slightly.

Inovio Biomedical (INO), a company involved in the development of DNA vaccines, said its partner Tripep AB of Sweden received approvals from the Swedish Medical Products Agency and local ethics committees to initiate a Phase I/II clinical trial of a novel DNA vaccine.

The vaccine is designed to treat chronically infected hepatitis C virus patients. Still, its shares dropped nearly 16% to $1.60.

Adventrx Pharmaceuticals (ANX), a biopharmaceutical research and development company, rose 3% to $2.32 on word that the Food and Drug Administration has granted the fast track designation for ANX-510, or CoFactor injection.

The product is currently being investigated in a Phase III study, with 5-fluorouracil and bevacizumab, for the initial treatment of metastatic colorectal cancer.

Winthrop Realty Trust (FUR) was initiated with a hold rating at KeyBanc, but that was good enough for investors, who lifted the real estate investment trust 15.3% to $6.80.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,389.00 53.72 0.35%
NASDAQ 3,507.43 11.00 0.31%
S&P 500 1,671.34 5.05 0.30%
US 10 Yr 1.944% -0.021

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs